"We Envision Growth Strategies Most Suited
to Your Business"

Anxiety Disorders and Depression Treatment Market to Register 2.6% CAGR till 2027; Growing Body of Research on Mental Illnesses to Catalyze the Market

January 28, 2021 | Healthcare

The global anxiety disorders and depression treatment market size is projected to reach USD 13.03 billion by 2027 owing to the expansion of online pharmacies in emerging economies, states Fortune Business Insights™ in its report, titled “Anxiety Disorders and Depression Treatment Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents, and Atypical Antipsychotics), By Indication (Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Phobia, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2020-2027”. The report finds that the value of the market was USD 8.50 billion in 2019 and that the market is expected to grow at a CAGR of 2.6% from 2020 to 2027.


The COVID-19 pandemic has proven to be a booster shot for the market for anxiety disorders and depression treatment due to an unprecedented rise in the demand for anti-anxiety and anti-depression drugs, triggered by strict social distancing measures, lockdowns, business closures, and disruptions in routine life. Big pharmaceutical companies, such as Pfizer and Cipla, reported a sudden spike in demand for anti-anxiety medications as the pandemic progressed in early 2020. As a result, the market exhibited a stellar CAGR of 28.2% and reached a value of USD 10.89 billion in 2020.


US FDA Approves Janssen’s Breakthrough Anti-Depression Therapy


Johnson & Johnson’s Janssen Pharmaceutical Companies announced that its CIII nasal spray, SPRAVATO, a unique formulation of esketamine, received clearance from the US Food and Drug Administration (FDA) in August 2020. The therapy has been created to manage symptoms in adults suffering from major depressive disorder with suicidal tendencies. The spray is also the first and only approved medication that has shown to lower the intensity of depressive symptoms within 24 hours. However, the efficacy of SPRAVATO in preventing suicidal ideation is yet to be investigated. Further, the use of the spray does not rule out hospitalization, if it is advised by the clinician.


To get a detailed report summary and research scope of this market, click here:


https://www.fortunebusinessinsights.com/anxiety-and-depression-treatment-market-102787


High Economic Burden of Depression and Anxiety to Fuel the Market


The physiological and psychological effects of anxiety and depression can take a heavy toll on a country’s economy and its healthcare system. According to the World Health Organization (WHO), disorders related to depression and anxiety cost the global economy USD 1 trillion every year. A loss of interest in work, hobbies, and physical activities and the harboring of suicidal thoughts have a paralytic effect on the productivity and efficiency of individuals. As a consequence, economic growth and development stumble, compelling governments to increase awareness about anxiety disorders and depression treatments. The global situation is being further exacerbated by the increasing prevalence of depression and anxiety disorders. The WHO estimates that 264 million people worldwide across all age groups suffer from depression, making it the foremost cause of disability globally. Between 1990 and 2013, the WHO’s recent study shows that the number of people affected by anxiety rose from 416 million to 615 million, indicating an increase of nearly 50% in a span of just 23 years. The adoption of anxiety disorders and depression treatment is, thus, likely to grow exponentially in the near future.


Strong Collaborations between Market Leaders to Stoke Innovation


Many of the key players in this market are entering into collaborations and partnerships with fellow participants and enhancing their capacity for innovation. These partnerships are enabling companies to expand their existing portfolios and diversify offerings, thus bolstering their market position. More importantly, the strengthening of research & development activities because of such collaborations is leading to the formulation of novel anxiety disorders and depression treatments, which will benefit the scores of people struggling with these disorders.


Industry Development:



  • June 2020: VistaGen Therapeutics entered into a licensing and collaboration agreement with EvenInsight Therapeutics for the development of VistaGen’s neurosteroid drug candidate for multiple anxiety-related disorders, PH94B. Under the agreement, the two companies will co-develop and commercialize the drug across Southeast Asia, South Korea, and Greater China.


List of Key Players Covered in the Anxiety Disorders and Depression Treatment Market Report:



  • AstraZeneca (Cambridge, U.K)

  • Eli Lilly and Company (Indiana, U.S)

  • GlaxoSmithKline plc (Brentford, U.K)

  • Pfizer Inc. (New York, U.S)

  • Bristol-Myers Squibb (New York, U.S)

  • Johnson & Johnson (New Jersey, U.S)

  • Merck & Co. Inc. (New Jersey, U.S)

  • H. Lundbeck A/S (Denmark, Europe)


Further Report Findings:



  • The anxiety segment is leading both the global market and the US market due to the growing prevalence of anxiety disorders worldwide, and particularly in the US.

  • North America is expected to dominate the anxiety disorders and depression treatment market share during the forecast period owing to the strong presence of large pharmaceutical companies in the US and frequent launch of novel products by these companies. In 2019, the North America market size stood at USD 4.44 billion.


Table of Segmentation


















































 ATTRIBUTE



  DETAILS



Study Period



  2016-2027



Base Year



  2019



Forecast Period



  2020-2027



Historical Period



  2016-2018



Unit



  Value (USD Billion)



Segmentation



  Drug Class; Indication; Distribution Channel; and Region



By Drug Class


 




  • Antidepressants

  • Anxiolytics

  • Anticonvulsants

  • Noradrenergic Agents

  • Atypical Antipsychotics



By Indication


 




  • Anxiety

  • Depression



By Distribution Channel


 




  • Hospital Pharmacy

  • Retail Pharmacy

  • Online Pharmacy



By Geography


 




  • North America (Drug Class; Indication; Distribution Channel)

    • USA (By Indication)

    • Canada (By Indication)



  • Europe (Drug Class; Indication; Distribution Channel)

    • The U.K. (By Indication)

    • Germany (By Indication)

    • France (By Indication)

    • Italy (By Indication)

    • Spain (By Indication)

    • Scandinavia (By Indication)

    • Rest of Europe (By Indication)



  • Asia Pacific (Drug Class; Indication; Distribution Channel)

    • Japan (By Indication)

    • China (By Indication)

    • India (By Indication)

    • Australia (By Indication)

    • Southeast Asia (By Indication)

    • Rest of Asia Pacific (By Indication)



  • Latin America (Drug Class; Indication; Distribution Channel)

    • Brazil (By Indication)

    • Mexico (By Indication)

    • Rest of Latin America (By Indication)



  • The Middle East & Africa (Drug Class; Indication; Distribution Channel)

    • GCC (By Indication)

    • South Africa (By Indication)

    • Rest of Middle East & Africa (By Indication)





 

Global Anxiety Disorders and Depression Treatment Market
  • PDF
  • 2019
  • 2016-2018
  • 135

    CHOOSE LICENSE TYPE

  • 4850
    5850
    6850

Our Clients

Bunge
Emerson
Panasonic
GM
Hitachi
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X